Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719656 | PMC |
Front Pharmacol
November 2018
Department of Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Interleukin-1 (IL-1) is the prototypical inflammatory cytokine: two distinct ligands (IL-1α and IL-1β) bind the IL-1 type 1 receptor (IL-1R1) and induce a myriad of secondary inflammatory mediators, including prostaglandins, cytokines, and chemokines. IL-1α is constitutively present in endothelial and epithelial cells, whereas IL-1β is inducible in myeloid cells and released following cleavage by caspase-1. Over the past 30 years, IL-1-mediated inflammation has been established in a broad spectrum of diseases, ranging from rare autoinflammatory diseases to common conditions such as gout and rheumatoid arthritis (RA), type 2 diabetes, atherosclerosis, and acute myocardial infarction.
View Article and Find Full Text PDFRheumatology (Oxford)
September 2017
Department of Rheumatology, University Hospital Basel, Basel, Switzerland.
Objectives: Pneumococcal, tetanus and influenza vaccinations are recommended for patients with cryopyrin-associated periodic syndromes (CAPS) when treated with immunosuppressive medication. The aim of this publication is to report the safety of pneumococcal and other vaccinations in CAPS patients.
Methods: All CAPS patients followed in the β-CONFIDENT (Clinical Outcomes and Safety Registry study of Ilaris patients) registry were analysed if they had received a vaccination.
Clin Exp Rheumatol
December 2015
Institute for Maternal and Child Health, IRCCS Burlo Garofolo, and University of Trieste, Trieste, Italy.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!